PT - JOURNAL ARTICLE AU - Mattioli, Francesca AU - Darvish, Hossein AU - Paracha, Sohail Aziz AU - Tafakhori, Abbas AU - Firouzabadi, Saghar Ghasemi AU - Chapi, Marjan AU - Azhar Baig, Hafiz Muhammad AU - Reymond, Alexandre AU - Antonarakis, Stylianos E. AU - Ansar, Muhammad TI - Biallelic truncation variants in <em>ATP9A</em> are associated with a novel autosomal recessive neurodevelopmental disorder AID - 10.1101/2021.05.31.21257832 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.31.21257832 4099 - http://medrxiv.org/content/early/2021/06/04/2021.05.31.21257832.short 4100 - http://medrxiv.org/content/early/2021/06/04/2021.05.31.21257832.full AB - Intellectual disability (ID) is a highly heterogeneous disorder with hundreds of associated genes. Despite progress in the identification of the genetic causes of ID following the introduction of high-throughput sequencing, about half of affected individuals still remain without a molecular diagnosis. Consanguineous families with affected individuals provide a unique opportunity to identify novel recessive causative genes.In this report we describe a novel autosomal recessive neurodevelopmental disorder. We identified two consanguineous families with homozygous variants predicted to alter the splicing of ATP9A which encodes a transmembrane lipid flippase of the class II P4-ATPases. The three individuals homozygous for these putatively truncating variants presented with severe ID, motor and speech impairment, and behavioral anomalies. Consistent with a causative role of ATP9A in these patients, a previously described Atp9a-/-mouse model showed behavioral changes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Swiss National Science Foundation (31003A_182632) and the Lejeune Foundation (JLF #1838) to AR and the Childcare Foundation to SEA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the IRBs of the Khyber Medical University, Peshawar, Pakistan, and the University Hospitals of Geneva, Switzerland (Protocol number: CER 11-036). Informed consent forms were obtained from guardians of all affected individuals who participated in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon request.